The FDA announced on July 2, 2012, that Hospira Inc. voluntarily recalled Carboplatin Injection due to failed pH specifications. The recall affects specific lots of 5 mL and 45 mL multi-dose vials distributed nationwide and in Puerto Rico.
How to tell if you have it
- Carboplatin Injection, 10 mg/mL
- NDC 61703-339-18 (Hospira label), lot Y031654AB, expiration APR2013
- NDC 61703-360-18 (Novoplus label), lot Y031654AA, expiration APR2013
- NDC 61703-339-50 (Hospira label), lots Y041711AA and Y061711AB, expirations DEC 2012 and FEB 2013
- NDC 61703-360-50 (Novoplus label), lot Y061711AA, expiration FEB 2013
The hazard
The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH. The FDA classified this Class III recall as voluntary and firm-initiated.
Context
GovInfoNow's records show Hospira Inc. has 108 other recalls on record since 2012-04-05. Other recent recalls of similar products include Cipla Diclofenac Gel Recall: Failed PH Specifications Risk (2025-12-22), Cipla Recalls Fosfomycin Tromethamine Granules Due to Impurities (2026-09-18), and Cipla Phytonadione Injectable Emulsion Recall: Stability Issues (2025-10-31).